Conference Call with Neuland Laboratories Management and Analysts on Q3FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Neuland Laboratories announced Q3FY26 results Revenue: Rs 447.8 lakh against Rs 401.9 lakh during Q3FY25, change 11%. EBITDA: Rs 85 lakh against Rs 90.3 lakh during Q3FY25, change -6%. EBITDA Margin: 19% for Q3FY26. PBT: Rs 54.3 lakh against Rs 127.5 lakh during Q3FY25, change -57%. PBT Margin: 12.1% for Q3FY26. PAT: Rs 40.4 lakh against Rs 101.4 lakh during Q3FY25, change -60%. Sucheth Davuluri, Vice-Chairman & Chief Executive Officer, said: “The revenues this quarter are in line with the outlook we envisaged for the year, however the product mix within businesses as well as increased operating expenses, is reflected in subdued EBITDA margins. We continue to see good momentum in the business which is driving our investments with the long-term in view, ensuring Neuland can take advantage of the number of growth opportunities.” Saharsh Davuluri, Vice Chairman & Managing Director, Neuland Laboratories, said: “We are seeing increasing interest from a wider range of customers interested in our capabilities as a proven commercial NCE drug substance manufacturer as well as an integral partner in the innovation journey. Our investments are leading to more engagements with existing customers while also attracting new customers who are looking for specific niche capabilities.” Result PDF